Online inquiry

IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7449MR)

This product GTTS-WQ7449MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ITGA2 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002203.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3673
UniProt ID P17301
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ7449MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14865MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ7512MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ10157MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ2746MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ8962MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ7981MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ1075MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ4374MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-188667
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW